iAnthus Capital Holdings (ITHUF) shows deeply negative equity recovery under a liquidation lens as of March 31, 2026. MFFAIS-reported CLV of negative $308M and LLV of negative $301M are consistent with the balance sheet: total assets of $255.8M against total liabilities of $372.7M yield book equity of negative $116.8M. Under liquidation haircuts, the deficit widens materially. Cash of $11.1M recovers at par. AR net of allowance ($6.75M) at 90-95% haircut contributes approximately $6.1-6.4M. Inventory of $24.6M at 60% haircut yields ~$14.7M. PP&E net book value of $106.2M at a 50-70% recovery range contributes $53-74M. Intangibles and goodwill ($1.6M goodwill, additional intangibles not separately broken out in XBRL but referenced in D&A disclosure of $2.3M quarterly amortization) recover at zero. Operating lease ROU assets ($28.9M) recover at zero while the corresponding ASC 842 lease liability ($33.5M) remains at face value. Long-term debt at carrying value is $198.7M (8% senior secured and unsecured debentures issued in the 2022 Recapitalization Transaction), which must be settled at face value. Accrued and other current liabilities are $48.1M, including $2.2M in related-party Deferred Professional Fees accruing at 8% following a February 2025 consent agreement that reduced principal by $6M and rate from 20%. Uncertain tax positions (Section 280E exposure) add a non-trivial but difficult-to-quantify claim: the filing discloses $6.1M in recognized unrecognized tax benefits and a Q1 2026 cash flow increase in uncertain tax position liabilities of $6.1M, with XBRL tagging of $70.6M in increases from current period tax positions — a figure that, if crystallized, would substantially worsen the liability stack. The company carries a going-concern qualification, working capital deficit of $21.9M, and accumulated deficit of $1,389.8M. Revenue declined 12.1% YoY to $33.5M for Q1 2026, driven by Florida price compression and the Arizona divestiture. The April 2026 medical cannabis rescheduling to Schedule III (AG Order 6754-2026) is discussed in MD&A as a potential 280E relief catalyst for medical operations but carries significant uncertainty and is not reflected in balance sheet positions. Filing discusses the 280E uncertain tax position extensively in MD&A but the magnitude of the gross unrecognized benefit ($70.6M tagged as current-period increases) is flagged separately in XBRL without clear balance sheet line reconciliation.
▼ Community Notes